ANBL2131: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

Disease Sites:

Not Available

Staging:

Phase III

Age Group:

Both

Therapies:

Chemotherapy - cytotoxic

Drugs:

Carboplatin, Cisplatin, Cyclophosphamide (CPM), Dexrazoxane, Doxorubicin, Etoposide, Filgrastim (GCSF), Irinotecan, Isotretinoin, Melphalan, Mesna, Myeloid Growth Factor, Sargramostim, TMZ, Temodar, Temozolomide (TMZ), Thiotepa, Topotecan, Unituxin (Dinutuximab), Vincristine

Principal Investigator(s):

Benedetti, Daniel

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

11-12-2024

Trial Type:

Treatment

Protocol ID:

VICC-NTPED24104

National Clinical Trial ID:

NCT06172296

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

ANBL2131: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

Eligibility